Senzo has raised $2.0M in total across 1 funding round.
Senzo's investors include BioAdvance, CP Ventures, LombardStreet Ventures, Mayfield, Social Capital.
Senzo is a life sciences company developing Amplified Lateral Flow (ALF) technology, which delivers PCR-accurate lateral flow tests for point-of-care diagnostics of major diseases like COVID-19, HIV, Flu A/B, Hepatitis C, Tuberculosis, and C. Difficile. These tests provide results in 10 minutes at a fraction of lab costs, targeting telemedicine, healthcare facilities, at-home use, and underserved areas to enable earlier treatment and better outcomes.[1][2][3] Founded in 2019 and based in London, England, Senzo has raised $6.45M in seed funding, including a $1.8M round two years ago, and holds 8 patents in analytical chemistry, chromatography, and immunologic tests.[1][2]
The company serves healthcare providers, consumers, and low-income regions by solving the problem of inaccessible, expensive lab-based diagnostics with high-sensitivity (over 10,000 times more than competitors), affordable, real-time alternatives that maintain 100% PCR accuracy.[2][3]
Senzo was founded in 2019 with the mission to create PCR-accurate point-of-care diagnostics for the world's deadliest diseases, addressing gaps in accessibility and cost.[1][2][3] Led by CEO Jeremy Stackawitz, the team emerged from expertise in life sciences to pioneer ALF technology, starting with applications for prevalent infections where early diagnosis drives impact.[2]
Early traction included a 2022 launch of an at-home COVID-19 test matching PCR reliability, followed by a $2M funding round at a $20M pre-money valuation to expand lateral flow options.[3][4] Pivotal moments feature partnerships like with BARDA and ISO 13485:2016 certification for quality management, solidifying its path to market.[2][4]
Senzo rides the point-of-care diagnostics boom, fueled by post-pandemic demand for rapid, decentralized testing amid rising telemedicine and at-home health trends.[2][3][4] Timing aligns with global needs for affordable diagnostics in resource-limited settings, where lab delays hinder treatment for diseases like TB and HIV, amplified by market forces like cost pressures on insurers and equity pushes in healthcare access.[1][2]
By decentralizing PCR-level accuracy, Senzo influences the ecosystem through expanded screening, earlier interventions, and data integration potential (e.g., via apps in similar platforms), challenging incumbents and enabling population health shifts.[1][3]
Senzo is poised to scale ALF across more diseases, leveraging its funding, patents, and certifications for regulatory approvals and global distribution.[1][2][4] Trends like AI-enhanced diagnostics, self-testing normalization, and emerging infectious threats will propel growth, potentially through acquisitions or pharma partnerships.[3]
Its influence may evolve by democratizing diagnostics, reducing healthcare disparities, and redefining routine testing—"as easy as taking a temperature"—ultimately amplifying impact where early detection saves lives, echoing its founding vision.[2]
Senzo has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $2.0M Seed | BioAdvance, CP Ventures, LombardStreet Ventures, Mayfield, Social Capital |
